Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 7/20 | 0.45 |
| ▸ | BRD2 | P25440 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | TOP1 | P11387 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL281586 | 0.80 | CES1 (0.55) | TGM2CA1CA2CA7CA9 | |
| SCHEMBL30397534 | 0.80 | CES1 (0.55) | TGM2CA1CA2CA7CA9 | |
| SCHEMBL12220595 | 0.73 | ACVR1 (0.50) | BRD4BRD2TGM2TDP1CHEK1 | |
| SCHEMBL21623878 | 0.73 | KMT2A (0.45) | TGM2CA1CA2CA7CA9 | |
| SCHEMBL21623877 | 0.73 | KMT2A (0.45) | TGM2CA1CA2CA7CA9 | |
| SCHEMBL8878421 | 0.72 | L3MBTL1 (0.53) | TGM2NPC1TDP1KMT2AMEN1 | |
| SCHEMBL7304930 | 0.68 | IDO1 (0.57) | BRD4BRD2TGM2NPC1TDP1 | |
| SCHEMBL30681308 | 0.68 | IDO1 (0.57) | BRD4BRD2TGM2NPC1TDP1 | |
| SCHEMBL17950677 | 0.68 | TOP1 (0.43) | TGM2CA1CA2CA7CA9 | |
| SCHEMBL8879202 | 0.68 | KMT2A (0.51) | TGM2CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122680-B2 | 3-Substituted oxindole β3 agonsists | ELI LILLY AND COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1341759-B1 | 3-SUBSTITUTED OXINDOLE BETA 3 AGONISTS | LILLY CO ELI (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050054713-A1 | 3-Substituted oxindole beta3 agonists | JESUDASON CYNTHIA DARSHINI (US) | 2005-03-10 | — | — | US | disclosed |
| US-6825220-B2 | INVOLVES THE RELATIONSHIP BETWEEN ADRENERGIC RECEPTOR STIMULATION AND ANTI-HYPERGLYCEMIC EFFECTS | ELI LILLY AND COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-20040097532-A1 | 3-Substituted oxindole beta 3 agonists | ELI LILLY AND COMPANY | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054713-A1 | 3-Substituted oxindole beta3 agonists | ADRB3, ADRB2, ADRB1 | BRD4 1073/4885BRD2 795/4885TGM2 4152/4885 |
| US-20040097532-A1 | 3-Substituted oxindole beta 3 agonists | ADRB3, ADRB2, ADRB1 | BRD4 1346/4885BRD2 987/4885TGM2 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.